Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. BMS’ Opdivo plus Yervoy for RCC to be available through NHS Scotland
  2. Diabetes Week: investigating the immune basis of type 1 diabetes
  3. Everest Medicines to commercialise Calliditas’ Nefecon in Greater China and Singapore
  4. AstraZeneca’s Calquence shows superiority to chemotherapy in CLL
  5. Researchers discover new drug target in tuberculosis

Latest Content

BMS’ Opdivo plus Yervoy for RCC to be available through NHS Scotland

Scotland’s healthcare pricing regulator the Scottish Medicines Consortium (SMC) has decided to fund Bristol Myers-Squibb (BMS)’s Opdivo (nivolumab) plus Yervoy (ipilimumab) for use in NHS Scotland for renal cell carcinoma (RCC) patients, who are previously untreated and considered to be of intermediate or poor prognostic risk.

Diabetes Week: investigating the immune basis of type 1 diabetes

Diabetes UK use its annual Diabetes Week to raise awareness, as well as funds for, among other things, crucial research into new treatments for diabetes. One largely neglected therapeutic approach the charity has invested in is repurposing immunotherapies from other autoimmune diseases for type 1 diabetes, linked with the immune system’s role in destroying pancreatic cells.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Close
Close
Close

Go Top